Rallybio Corp
RLYB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001739410
In the last 90 days, Rallybio Corp insiders filed 0 open-market purchases and 1 sale; 37 institutions reported holding it in 13F filings for Q2 2026, worth $65.0M in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 28, 2026, 12:35 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $8.98M (1046.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 13, 2025 | Feb 6, 2024 | Mar 6, 2023 | Mar 15, 2022 |
| Revenue | $858.0K | $600.0K | – | – | – |
| Operating expenses | $33.9M | $61.1M | $78.9M | $67.9M | $45.6M |
| Research and development | $19.6M | $41.5M | $53.5M | $40.7M | $26.9M |
| Selling, general and administrative | $14.3M | $19.6M | $25.4M | $27.2M | $18.7M |
| Operating income | -$33.1M | -$60.5M | -$78.9M | -$67.9M | -$45.6M |
| Interest expense | – | – | – | $0 | $10.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.98M | -$57.8M | -$74.6M | -$66.7M | -$47.0M |
| EPS, basic | $-1.59 | $-1.33 | $-1.84 | $-2.09 | – |
| EPS, diluted | $-1.59 | $-1.33 | $-1.84 | $-2.09 | – |
| Weighted shares, basic | 5.63M | 43.5M | 40.4M | 31.8M | – |
| Weighted shares, diluted | 5.63M | 43.5M | 40.4M | 31.8M | – |
| Margins and growth | |||||
| Operating margin | -3853.6% | -10082.7% | – | – | – |
| Net margin | -1046.4% | -9629.2% | – | – | – |
| Revenue growth, year over year | +43.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 13, 2025 | Feb 6, 2024 | Mar 6, 2023 | Mar 15, 2022 |
| Cash and equivalents | $31.4M | $13.9M | $24.5M | $57.0M | $175.3M |
| Short-term investments | $23.4M | $51.6M | $85.4M | $112.0M | – |
| Total current assets | $61.3M | $67.8M | $114.8M | $179.5M | $180.9M |
| Property, plant and equipment | $23.0K | $115.0K | $246.0K | $385.0K | $511.0K |
| Total assets | $62.3M | $68.1M | $115.6M | $180.4M | $182.2M |
| Accounts payable | $126.0K | $278.0K | $976.0K | $1.11M | $603.0K |
| Total current liabilities | $4.22M | $6.24M | $9.26M | $10.7M | $6.55M |
| Total liabilities | $4.30M | $6.45M | $9.44M | $11.1M | $6.58M |
| Shareholders' equity | $58.0M | $61.7M | $106.2M | $169.3M | $175.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 13, 2025 | Feb 6, 2024 | Mar 6, 2023 | Mar 15, 2022 |
| Operating cash flow | -$29.8M | -$49.3M | -$60.3M | -$57.3M | -$45.5M |
| Capital expenditures | – | $0 | $12.0K | $54.0K | $333.0K |
| Free cash flow | – | -$49.3M | -$60.3M | -$57.3M | -$45.9M |
| Depreciation and amortization | $92.0K | $131.0K | $150.0K | $167.0K | $109.0K |
| Stock-based compensation | $5.31M | $7.99M | $10.9M | $9.50M | $3.65M |
| Investing cash flow | $47.3M | $33.5M | $27.7M | -$112.2M | -$2.33M |
| Financing cash flow | $16.0K | $5.20M | $143.0K | $51.1M | $83.0M |
| Net change in cash | $17.5M | -$10.6M | -$32.5M | – | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 619.3% | 1332.2% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 20, 2026 | 5.38M | −87.3% | SEC |
| Jul 30, 2026 | 5.31M | −87.3% | SEC |
| May 8, 2026 | 5.30M | −87.3% | SEC |
| Mar 6, 2026 | 5.29M | −87.3% | SEC |
| Oct 31, 2025 | 42.2M | +1.8% | SEC |
| Aug 1, 2025 | 41.8M | +0.7% | SEC |
| May 2, 2025 | 41.6M | +0.4% | SEC |
| Mar 7, 2025 | 41.6M | +10.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-8 in Q1 2026.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.